Payer and Manufacturer Agreements for High-Cost Therapy: A Narrative Review
Published online on May 05, 2026
Abstract
Journal of Pharmacy Practice, Ahead of Print.
Between 2022 and 2025, several ultra–high-cost, one-time therapies were approved in the United States, offering potentially curative options for conditions such as spinal muscular atrophy, hemophilia, and sickle cell disease. Despite their clinical value, ...
Between 2022 and 2025, several ultra–high-cost, one-time therapies were approved in the United States, offering potentially curative options for conditions such as spinal muscular atrophy, hemophilia, and sickle cell disease. Despite their clinical value, ...